Videos

Dual HER2 blockade with pertuzumab and trastuzumab plus chemotherapy for the treatment of HER2-positive metastatic breast cancer improved median OS by almost 16 months over standard first-line therapy.

Sandra M. Swain, MD, discusses final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.

The concept of targeting mitotic cell division to halt the progression of rapidly dividing cancer cells has long been a staple of oncology therapy, yet chemotherapy agents that are the prime examples of this approach are nonselective in their action and can kill normal and malignant cells alike.

Treatment with the combination of bevacizumab and chemotherapy improved PFS and OS in women with HER2-negative metastatic breast cancer.

Niraj Mehta, MD, Radiation Oncologist, 21st Century Oncology, discusses the reliability of automated segmentation for lung volumes in breast, lung, and esophageal cancers.

More than one-third of patients with breast or ovarian cancer or a family history of those diseases who also saw a genetic counselor did not pursue genetic testing for BRCA 1 or BRCA 2 mutations.

Although universal insurance coverage for postmastectomy breast reconstruction has been mandated since 1998, a new study has found that the persistently high rates of American women who choose not to undergo reconstruction surgery are due primarily to patient preferences and not a lack of awareness.

Deanna J. Attai, MD, discusses a 5-year follow up of patients receiving accelerated partial breast irradiation (APBI) using strut-based applicators.

Treatment strategies that incorporate pertuzumab (Perjeta) continue to evolve as more clinical trial data becomes available.

The combination of letrozole with either the CDK4/6 inhibitor LEE011 or the PI3 kinase Inhibitor BYL719 demonstrated clinical activity for women with ER-positive, HER2-negative breast cancer.

Data from a brand new survey addressed some of the emotional issues faced by physicians when treating and delivering a diagnosis of advanced breast cancer.

Sara Hurvitz, MD, highlights key points on the PIK3CA mutation, and addresses several other key topics in the field of breast cancer.

Julie R. Gralow, MD, discusses the use of bisphosphonates in early-stage breast cancer.

Elisa K. Chan, MD, discusses improving mammography screening rates with signed letters from physicians. Chan worked for the BC Cancer Agency during the study.

The addition of trastuzumab to fulvestrant prolonged responses compared with fulvestrant alone for certain patients with metastatic breast cancer.

A novel HER2-derived peptide vaccine designed to stimulate CD8+ cytotoxic T-lymphocytes reduced the rate of breast cancer recurrence and proved safe and well tolerated in the adjuvant setting.

The PARP inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA-wild type tumors.

Long-term follow-up of a phase III clinical trial shows strong trends toward a greater likelihood of resuming menses and becoming pregnant when a luteinizing hormone-releasing hormone (LH-RH) analog is administered with chemotherapy in patients with breast cancer

Breast conserving therapy (BCT) improves overall survival compared with other local treatments in patients with stage I breast cancer, according to an examination of the National Cancer Database (NCDB).

Mark Sisco, MD, Clinical Assistant Professor, Division of Plastic and Reconstructive Surgery, NorthShore Univeristy HealthSystem, discusses the results of a NSQIP analysis of 30-day complications after bilateral versus unilateral mastectomy with immediate reconstruction

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in early-stage breast cancer.

Although hormone-targeting strategies have been a mainstay of prostate and breast cancer therapies for decades, an improved understanding of the mechanisms underlying these malignancies has led researchers to focus fresh attention on the complex activity of the androgen receptor (AR) as a point of attack.

The American Society of Clinical Oncology (ASCO) has released a new clinical practice guideline on the treatment of patients with advanced HER2-negative breast cancer.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, provides an overview of the SystHERs registry.